Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505)
8.28+0.01+0.12%
Market data delayed 15 minutes
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
No Content- Fudan-Zhangjiang Bio-Pharmaceutical Invests 200 Million Yuan in Structured Deposit ProductFudan-Zhangjiang Bio-Pharmaceutical Invests 200 Million Yuan in Structured Deposit Product
MT Newswires Live · 04-03 12:51
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Agreed to Subscribe for Structured Deposit Product for RMB200 MlnShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Agreed to Subscribe for Structured Deposit Product for RMB200 Mln
THOMSON REUTERS · 04-02
- BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical To Subscribe For Structured Deposit ProductBRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical To Subscribe For Structured Deposit Product
Reuters · 04-01
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical- to Subscribe for Structured Deposit Product of RMB220 Mln From Spd BankShanghai Fudan-Zhangjiang Bio-Pharmaceutical- to Subscribe for Structured Deposit Product of RMB220 Mln From Spd Bank
THOMSON REUTERS · 04-01
- Fudan-Zhangjiang Bio-Pharmaceutical's Profit, Revenue Drop in 2024Fudan-Zhangjiang Bio-Pharmaceutical's Profit, Revenue Drop in 2024
MT Newswires Live · 03-28
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical FY Dividend RMB 0.03Shanghai Fudan-Zhangjiang Bio-Pharmaceutical FY Dividend RMB 0.03
THOMSON REUTERS · 03-27
- Fudan-Zhangjiang Bio-Pharmaceutical Enrolls First Patient in Bladder Cancer StudyFudan-Zhangjiang Bio-Pharmaceutical Enrolls First Patient in Bladder Cancer Study
MT Newswires Live · 03-14
- Fudan-Zhangjiang Bio-Pharmaceutical's 2024 Profit Plunges 63%Fudan-Zhangjiang Bio-Pharmaceutical's 2024 Profit Plunges 63%
MT Newswires Live · 02-28
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical FY Revenue RMB 709.4 MillionShanghai Fudan-Zhangjiang Bio-Pharmaceutical FY Revenue RMB 709.4 Million
THOMSON REUTERS · 02-27
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 MillionShanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees FY Unaudited Net Profit Attributable RMB35 Million To RMB52 Million
Reuters · 01-17
- Fudan-Zhangjiang Bio-Pharma Expects Up to 68% Lower Net Profit in 2024Fudan-Zhangjiang Bio-Pharma Expects Up to 68% Lower Net Profit in 2024
MT Newswires Live · 01-17
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees Unaudited Net Profit Attributable RMB35 Mln to RMB52 Mln for YearShanghai Fudan-Zhangjiang Bio-Pharmaceutical Sees Unaudited Net Profit Attributable RMB35 Mln to RMB52 Mln for Year
THOMSON REUTERS · 01-17
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical- Subscription of Structured Deposit Product for RMB200 MlnShanghai Fudan-Zhangjiang Bio-Pharmaceutical- Subscription of Structured Deposit Product for RMB200 Mln
THOMSON REUTERS · 01-08
- BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes RMB200 Mln Structured Deposit ProductBRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes RMB200 Mln Structured Deposit Product
Reuters · 01-03
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - to Subscribe for Corporate Structured Deposit Product of Ping an BankShanghai Fudan-Zhangjiang Bio-Pharmaceutical - to Subscribe for Corporate Structured Deposit Product of Ping an Bank
THOMSON REUTERS · 01-03
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Subscription of Structured Deposit Product of RMB200 MlnShanghai Fudan-Zhangjiang Bio-Pharmaceutical - Subscription of Structured Deposit Product of RMB200 Mln
THOMSON REUTERS · 01-02
- China Accepts Shanghai Fudan-Zhangjiang Bio-Pharma's Drug Application for Obeticholic Acid TabletsChina Accepts Shanghai Fudan-Zhangjiang Bio-Pharma's Drug Application for Obeticholic Acid Tablets
MT Newswires Live · 2024-11-01
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Received Acceptance Notice by Nmpa for Abbreviated New Drug Application for Obeticholic Acid TabletsShanghai Fudan-Zhangjiang Bio-Pharmaceutical - Received Acceptance Notice by Nmpa for Abbreviated New Drug Application for Obeticholic Acid Tablets
THOMSON REUTERS · 2024-10-31
- Fudan-Zhangjiang Bio-Pharma's Q3 Profit Slides 25%Fudan-Zhangjiang Bio-Pharma's Q3 Profit Slides 25%
MT Newswires Live · 2024-10-25
Company Profile
Company Name上海复旦张江生物医药股份有限公司Industry医药制造业Listing Date2020-06-19Registered Capital10365万元Introduction上海复旦张江生物医药股份有限公司的主营业务是从事生物医药的创新研究开发、生产制造和市场营销。公司的主要产品是盐酸氨酮戊酸外用散、注射用海姆泊芬、长循环盐酸多柔比星脂质体注射液。IPO Information
Listing Date- -Issue Price- -
- 1D
- 5D
- Day
- Week
- Month
Loading ...
High
8.44
Open
8.24
T/O Rate
0.54%
Low
8.21
Close
8.27
Amplitude
2.78%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial